Press Releases

Connected Living Teams Up with UsAgainstAlzheimer’s, Sodexo and other Leading Organizations to Support Families for World Alzheimer’s Day

September 14, 2017

In recognition of World Alzheimer’s Day, Connected Living, a provider of social networking services to families and senior citizens, announced today that it has pledged to donate 15 percent of all proceeds from their app services to UsAgainstAlzheimer's (UsA2), an innovative nonprofit organization demanding – and delivering – a solution to Alzheimer’s.

UsAgainstAlzheimer’s Secures Major Award to Advance Latino and African American Community-Based Alzheimer’s Priorities

February 2, 2017

WASHINGTON, DC, February 2, 2017—To address the underrepresentation of African Americans and Latinos in all aspects of neurological research, UsAgainstAlzheimer’s has launched a multi-pronged engagement strategy to build a national network of diverse researchers, patients, caregivers and stakeholder groups for collaboration and knowledge sharing around barriers, facilitators and priorities in Alzheimer’s research. The project aims to foster effective and inclusive community engagement and collaboration strategies.

UsAgainstAlzheimer’s Proud to Be a Founding Partner of Dementia Friendly America and its New Dementia Friends Initiative

January 19, 2017

WASHINGTON, DC—Dementia Friendly America (DFA), a national collaborative representing the nation’s leading Alzheimer’s organizations, companies and advocates, recently announced the U.S. launch of the Dementia Friends program, a global initiative that aims to empower and educate individuals about dementia. UsAgainstAlzheimer’s, a funding partner of DFA, is pleased to be a fervent initiator and supporter of this effort to serve the millions of people and their caregivers affected by Alzheimer’s disease.

Recent Alzheimer’s Drug Disappointment Illuminates Pathway for Progress against the Disease

January 12, 2017

Open Letter from UsAgainstAlzheimer’s Co-Founder and Chairman Specifies Initial Next Steps to Achieve Critical Advancements Toward Effective Treatments and a Cure

WASHINGTON, DC—In a letter released today by UsAgainstAlzheimer’s, Co-Founder and Chairman George Vradenburg said the negative clinical trial of a once-promising Alzheimer’s drug, Solanezumab, which showed clinically insignificant ability to slow cognitive decline in Alzheimer’s patients, should be viewed not as a failure, but as a development that “provides valuable lessons and suggests a way forward in the fight against Alzheimer’s.”

UsAgainstAlzheimer’s Applauds Passing of 21st Century Cures Act – A Much-Needed Boost in the Goal to Develop an Alzheimer’s Cure by 2025

December 7, 2016

WASHINGTON, DC—Following the passing of the 21st Century Cures Act by the U.S. Senate on Wednesday, UsAgainstAlzheimer’s applauds the bipartisan action by Congress to hasten and strengthen the nation’s abilities to develop, test and deliver game-changing therapies for diseases and illnesses that cripple families.